Cargando…

617. Long Acting Lipoglycopeptide Use in Veterans for Serious Gram-Positive Infections in the COVID Era

BACKGROUND: Dalbavancin and Oritavancin are semisynthetic lipoglycopeptides (LGP) that are FDA-approved for treatment of skin and soft tissue infections, but emerging data supports LGP use for other serious gram positive (GP) infections. We describe our experience with LGP during the COVID-19 pandem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saldana, Carlos S, Goolsby, Tiffany, Epstein, Lauren H, Oliver, Nora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644193/ http://dx.doi.org/10.1093/ofid/ofab466.815

Ejemplares similares

614. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics
por: Metzger, Brian S, et al.
Publicado: (2020)

44. Cost Effectiveness and Clinical Outcomes of Long Acting Lipoglycopeptides Used in Transitions of Care for Deep-Seated Infections
por: Antosz, Kayla S, et al.
Publicado: (2021)

Long-Acting Lipoglycopeptides: “Lineless Antibiotics” for Serious Infections in Persons Who Use Drugs
por: Morrisette, Taylor, et al.
Publicado: (2019)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

231. Retrospective Comparison of Intravenous Therapy, Oral Therapy, and Lipoglycopeptides for the Treatment of Osteomyelitis
por: Stumphauzer, Alex, et al.
Publicado: (2021)

Long-Acting Lipoglycopeptides for Gram-Positive Bacteremia at the End of Life to Facilitate Hospice Care: A Report of 3 Cases
por: Datta, Rupak, et al.
Publicado: (2018)

587. An Intervention to Improve COVID-19 Vaccination Rates Among Inpatients at a Veterans Affairs Hospital
por: Fujita, Ayako, et al.
Publicado: (2021)

Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
por: Smith, Jordan R., et al.
Publicado: (2015)

544. Using Active Surveillance to Identify Monoclonal Antibody Candidates Among COVID-19 Positive Veterans, Atlanta VA Healthcare System
por: Paras, Alexander T, et al.
Publicado: (2021)

1301. Assessing Safety and Clinical Outcomes of Outpatient Parenteral Antimicrobial Program in Veterans
por: Rich, William, et al.
Publicado: (2023)

Shifts in Multiple Myeloma Care Utilization of Veterans in the COVID-19 Era: Interrupted Time Series Analysis of Veterans Health Administration Data
por: Su, Christopher T, et al.
Publicado: (2022)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

2938. Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era within the US Veterans Health Administration
por: Varley, Cara D, et al.
Publicado: (2023)

170. Comparison of Traditional Stool Culture and Targeted Testing Using Multiplex PCR to Diagnose Infectious Diarrhea at the Atlanta VA Medical Center (AVAMC): A Diagnostic Stewardship Initiative.
por: Molinari, Alexander H, et al.
Publicado: (2022)

285. Evaluation of the ePlex® Blood Culture Identification (BCID) Panels for Gram-positive/Gram-negative bacteria and yeasts
por: Chapin, Kimberle, et al.
Publicado: (2020)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

1878. Expanding Kentucky’s “One and Done” Tradition: Lipoglycopeptide Administration in the Emergency Department at a Tertiary, Academic Medical Center
por: Burgess, Donna R, et al.
Publicado: (2018)

1353. Gonorrhea and Chlamydia Testing and Case Rates Among Women Veterans in the Veterans Health Administration
por: Keddem, Shimrit, et al.
Publicado: (2021)

82. Assessment of Clinical Outcomes and Antibiotic Prescribing Patterns Following Implementation of the GenMark ePlex(®) Blood Culture Identification Panel for Gram-positive Bloodstream Infections
por: Wein, Megan, et al.
Publicado: (2021)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection
por: Alosaimy, Sara, et al.
Publicado: (2020)

687. Use of Dalbavancin in Gram-positive Infective Endocarditis: Review of Current Literature
por: Fazili, Tasaduq, et al.
Publicado: (2021)

156. Evaluation of Trends in Antimicrobial Use and Proportion of Culture Positive Gram-Negative/Gram-Positive Pathogens Comparing Prior to and During the SARS-CoV-2 Pandemic: A Multicenter Evaluation
por: Puzniak, Laura A, et al.
Publicado: (2021)

617. Physician Perspective: Utilization of Advanced Practice Providers (APPs) in the ID Workforce
por: Beieler, Alison M, et al.
Publicado: (2020)

146. Outpatient Antibiotic Stewardship in the COVID Era: Trends in antibiotic prescription in a statewide Veteran’s Affairs health care system
por: Werzen, Alissa, et al.
Publicado: (2020)

2225. Acute Hepatitis C Virus Infections in HIV-Infected Persons in the Era of Direct-Acting Antiviral Therapy
por: Cartwright, Emily J, et al.
Publicado: (2018)

143. Modification of Linezolid Restriction Criteria Reduces ICU Gram-positive Antibiotic Consumption
por: Boulos, John M, et al.
Publicado: (2020)

Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide Antibiotics
por: Sur, Vishma Pratap, et al.
Publicado: (2021)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

191. Oral Antibiotic Step-Down Therapy for Non-Staphylococcal Gram-Positive Bloodstream Infections
por: Gandhi, Kelvin, et al.
Publicado: (2021)

Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics
por: Eckmann, Christian, et al.
Publicado: (2021)

Engaging Older Veterans With Serious Mental Illness in Physical Activity: In-Person, Remote, and Hybrid Models
por: Muralidharan, Anjana, et al.
Publicado: (2021)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial
por: McCarthy, Matthew W, et al.
Publicado: (2019)

2219. Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study
por: Butt, Adeel Ajwad, et al.
Publicado: (2018)

258. A Comparison of Cefprozil and Fluoroquinolones for Gram-Negative Bacteremia
por: Nolen, Rebecca C, et al.
Publicado: (2020)

2811. Real-World Experience Utilizing Cefiderocol for Serious Multidrug Resistant Gram-Negative Infections
por: Teran, Nicholas S, et al.
Publicado: (2023)

964. Real-world dalbavancin use for serious gram-positive bacterial infections: comparing outcomes between people who use and do not use drugs
por: Zambrano, Sarah, et al.
Publicado: (2023)

Nurse-Driven Transitions Program Provides High Value End-of-Life Care to Veterans With Serious Illness
por: Driver, Jane, et al.
Publicado: (2020)

200. Prospective Evaluation of the GenMark Dx ePlex(®) Blood Culture Identification Gram Positive Panel
por: Meeder, Jeremy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mbqf7s264689e0cg12jsg2jr5f